I hold Avita and have seen how much the market slams companies when it looks like revenue growth is struggling to deal with cost escalation. And if the market sniffs a near term CR then the SP gets crushed. That said it wouldn't be hard to find some still a way off profitability and with revenue not much higher than Eye but much bigger market caps. At $51 million and around a PS ratio of 2 I can only call this undervalued. That only makes sense though if you're playing a longer game which is my situation.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-273
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
-0.005(2.63%) |
Mkt cap ! $42.37M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $69.95K | 368.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 151260 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 109576 | 2 |
View Market Depth
| Last trade - 12.37pm 09/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |